Nanoscale particulate systems for multidrug delivery: Towards improved combination chemotherapy

Therapeutic Delivery

Volumn 5, Issue 2, 2014, Pages 149-171

  Liboiron, Barry D ^a   Mayer, Lawrence D ^a  

^a Celator Pharmaceuticals Corp   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN INHIBITOR; PROTEIN INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SENSITIZATION; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCREENING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 84893331612     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.149     Document Type: Review

References (102)

1. Binkhathlan Z, Alshamsan A. Emerging nanodelivery strategies of RNAi molecules for colon cancer therapy: preclinical developments. Ther. Deliv. 3(9), 1117-1130 (2012).
2. Sui H, Fan ZZ, Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J. Int. Med. Res. 40(2), 426-435 (2012).
3. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist. Updat. 15(1-2), 62-69 (2012).
4. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist. Updat. 15(1-2), 50-61 (2012).
5. Thomas S, Quinn BA, Das SK et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin. Ther. Targets 17(1), 61-75 (2012).
6. Fulda S. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies. Leukemia 26(6), 1155-1165 (2012).
7. Arlt A, Muerkoster SS, Schafer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 332(2), 346-358 (2013).
8. Breccia M, Alimena G. NF-kappaB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin. Ther. Targets 14(11), 1157-1176 (2010).
9. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol. Cell. Biochem. 336(1-2), 25-37 (2010).
10. Salminen A, Ojala J, Kaarniranta K. Apoptosis and aging: increased resistance to apoptosis enhances the aging process. Cell. Mol. Life Sci. 68(6), 1021-1031 (2011).
11. Hu CM, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr. Drug. Metab. 10(8), 836-841 (2009).
12. Kettiger H, Schipanski A, Wick P, Huwyler J. Engineered nanomaterial uptake and tissue distribution: from cell to organism. Int. J. Nanomedicine 8, 3255-3269 (2013).
13. Treuel L, Jiang X, Nienhaus GU. New views on cellular uptake and trafficking of manufactured nanoparticles. J. R. Soc. Interface 10(82), 20120939 (2013).
14. Song XR, Cai Z, Zheng Y et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci. 37(3-4), 300-305 (2009).
15. Wu J, Lu Y, Lee A et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10(3), 350-357 (2007).
16. Wang J, Goh B, Lu W et al. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharm. Bull. 28(5), 822-828 (2005).
17. Prior RL. Fruits and vegetables in the prevention of cellular oxidative damage. Am. J. Clin. Nutr. 78(Suppl. 3), 570S-578S (2003).
18. Song X, Zhao Y, Hou S et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur. J. Pharm. Biopharm. 69(2), 445-453 (2008).
19. Song X, Zhao Y, Wu W et al. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int. J. Pharm. 350(1-2), 320-329 (2008).
20. Wong MY, Chiu GN. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine 7(6), 834-840 (2011).
21. Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell. Biochem. 296(1-2), 85-95 (2007).
22. Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV, Limtrakul P. Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother. Pharmacol. 57(3), 376-388 (2006).
23. Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 6(3), 928-939 (2009).
24. Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly(d,l-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol. Pharm. 8(3), 852-866 (2011).
25. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 136(1), 21-29 (2009).
26. Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res. Treat. 119(2), 255-269 (2010).
27. Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control. Release 116(3), 275-284 (2006).
28. Gill KK, Kaddoumi A, Nazzal S. Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines. Eur. J. Pharm. Sci. 46(1-2), 64-71 (2012).
29. Shieh MJ, Hsu CY, Huang LY, Chen HY, Huang FH, Lai PS. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J. Control. Release 152(3), 418-425 (2011).
30. Vicentini FT, Borgheti-Cardoso LN, Depieri LV et al. Delivery systems and local administration routes for therapeutic siRNA. Pharm. Res. 30(4), 915-931 (2013).
31. Rehman Z, Zuhorn IS, Hoekstra D. How cationic lipids transfer nucleic acids into cells and across cellular membranes: recent advances. J. Control. Release 166(1), 46-56 (2013).
32. Khatri N, Rathi M, Baradia D, Trehan S, Misra A. In vivo delivery aspects of miRNA, shRNA and siRNA. Crit. Rev. Ther. Drug Carrier Syst. 29(6), 487-527 (2012).
33. Pakunlu RI, Wang Y, Tsao W, Pozharov V, Cook TJ, Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res. 64(17), 6214-6224 (2004).
34. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond.) 3(6), 761-776 (2008).
35. Garbuzenko OB, Saad M, Betigeri S et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm. Res. 26(2), 382-394 (2009).
36. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc. Natl Acad. Sci. USA 107(23), 10737-10742 (2010).
37. Chen AM, Zhang M, Wei D et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5(23), 2673-2677 (2009).
38. Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target. 19(10), 900-914 (2011).
39. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int. J. Pharm. 367(1-2), 195-203 (2009).
40. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31(2), 358-365 (2010).
41. Chen Y, Bathula SR, Li J, Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J. Biol. Chem. 285(29), 22639-22650 (2010).
42. Chen Y, Sen J, Bathula SR, Yang Q, Fittipaldi R, Huang L. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol. Pharm. 6(3), 696-705 (2009).
43. Cheng D, Cao N, Chen J, Yu X, Shuai X. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. Biomaterials 33(4), 1170-1179 (2012).
44. Cao N, Cheng D, Zou S, Ai H, Gao J, Shuai X. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials 32(8), 2222-2232 (2011).
45. Zou S, Cao N, Cheng D et al. Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin. Int. J. Nanomedicine 7, 3823-3835 (2012).
46. Xiao Y, Jaskula-Sztul R, Javadi A et al. Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 4(22), 7185-7193 (2012).
47. Inoue S, Ding H, Portilla-Arias J et al. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res. 71(4), 1454-1464 (2011).
48. Ding H, Helguera G, Rodriguez JA et al. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. J. Control. Release 171(3), 322-329 (2013).
49. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Pharm. Sci. 97(11), 4696-4740 (2008).
50. Jiang J, Yang SJ, Wang JC et al. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur. J. Pharm. Biopharm. 76(2), 170-178 (2010).
51. Sengupta S, Eavarone D, Capila I et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436(7050), 568-572 (2005).
52. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur. J. Pharm. Biopharm. 74(3), 467-473 (2010).
53. Wang Z, Chui WK, Ho PC. Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm. Res. 28(3), 585-596 (2011).
54. Wang Z, Ho PC. A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 31(27), 7115-7123 (2010).
55. Aw MS, Addai-Mensah J, Losic D. A multi-drug delivery system with sequential release using titania nanotube arrays. Chem. Commun. (Camb) 48(27), 3348-3350 (2012).
56. Erler JT, Linding R. Network-based drugs and biomarkers. J. Pathol. 220(2), 290-296 (2010).
57. Agrawal V, Paul MK, Mukhopadhyay AK. 6-mercaptopurine and daunorubicin double drug liposomes-preparation, drug-drug interaction and characterization. J. Liposome Res. 15(3-4), 141-155 (2005).
58. Na HS, Lim YK, Jeong YI et al. Combination antitumor effects of micelle-loaded anticancer drugs in a CT-26 murine colorectal carcinoma model. Int. J. Pharm. 383(1-2), 192-200 (2010).
59. Shin HC, Alani AW, Rao DA, Rockich NC, Kwon GS. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J. Control. Release 140(3), 294-300 (2009).
60. Katragadda U, Teng Q, Rayaprolu BM, Chandran T, Tan C. Multi-drug delivery to tumor cells via micellar nanocarriers. Int. J. Pharm. 419(1-2), 281-286 (2011).
61. Katragadda U, Fan W, Wang Y, Teng Q, Tan C. Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS ONE 8(3), e58619 (2013).
62. Devalapally H, Duan Z, Seiden MV, Amiji MM. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int. J. Cancer 121(8), 1830-1838 (2007).
63. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual-drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31(13), 3694-3706 (2010).
64. Zucker D, Andriyanov AV, Steiner A, Raviv U, Barenholz Y. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J. Control. Release 160(2), 281-289 (2012).
65. Zucker D, Barenholz Y. Optimization of vincristine-topetecan combination-paving the way for improved chemotherapy regimens by nanoliposomes. J. Control. Release 146(3), 326-333 (2010).
66. Zhang L, Radovic-Moreno AF, Alexis F et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chem. Med. Chem. 2(9), 1268-1271 (2007).
67. Kolishetti N, Dhar S, Valencia PM et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl Acad. Sci. USA 107(42), 17939-17944 (2010).
68. Ansell SM, Johnstone SA, Tardi PG et al. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. J. Med. Chem. 51(11), 3288-3296 (2008).
69. Lee SM, O'Halloran TV, Nguyen ST. Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J. Am. Chem. Soc. 132(48), 17130-17138 (2010).
70. Vicent MJ, Greco F, Nicholson RI, Paul A, Griffiths PC, Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew. Chem. Int. Ed. Engl. 44(26), 4061-4066 (2005).
71. Greco F, Vicent MJ, Gee S et al. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J. Control. Release 117(1), 28-39 (2007).
72. Lammers T, Subr V, Ulbrich K et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30(20), 3466-3475 (2009).
73. Bae Y, Diezi TA, Zhao A, Kwon GS. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J. Control. Release 122(3), 324-330 (2007).
74. Yin C, Li X, Wu Q, Wang JL, Lin XF. Multidrug nanoparticles based on novel random copolymer containing cytarabine and fluorodeoxyuridine. J. Colloid Interface Sci. 349(1), 153-158 (2010).
75. Aryal S, Hu CM, Zhang L. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol. Pharm. 8(4), 1401-1407 (2011).
76. Ahmed F, Pakunlu RI, Brannan A, Bates F, Minko T, Discher DE. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J. Control. Release 116(2), 150-158 (2006).
77. Chen W, Meng F, Cheng R, Zhong Z. pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles. J. Control. Release 142(1), 40-46 (2010).
78. Chiang CS, Hu SH, Liao BJ, Chang YC, Chen SY. Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds. Nanomedicine 10(1), 99-107 (2014).
79. Abraham SA, Mckenzie C, Masin D et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin. Cancer Res. 10(2), 728-738 (2004).
80. Liboiron BD, Tardi PG, Harasym TO, Mayer LD. Nanoscale delivery systems for combination chemotherapy. In: Drug Delivery in Oncology: From Basic Research to Cancer Therapy. Kratz F, Senter P, Steinhagen H (Eds). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 1013-1050 (2012).
81. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
82. Tardi PG, Dos Santos N, Harasym TO et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol. Cancer Ther. 8(8), 2266-2275 (2009).
83. Harasym TO, Tardi PG, Harasym NL, Harvie P, Johnstone SA, Mayer LD. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol. Res. 16(8), 361-374 (2007).
84. Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol. Interv. 7(4), 216-223 (2007).
85. Harasym TO, Liboiron BD, Mayer LD. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Methods Mol. Biol. 596, 291-323 (2010).
86. Mayer LD, Harasym TO, Tardi PG et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5(7), 1854-1863 (2006).
87. Tardi P, Johnstone S, Harasym N et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk. Res. 33(1), 129-139 (2009).
88. Harasym TO, Tardi PG, Johnstone SA, Mayer LD, Bally MB, Janoff AS. Fixed drug ratio liposome formulations of combination cancer therapeutics. In: Liposome Technology (3rd edition) Volume III: Interactions of Liposomes with Biological Milieu. Gregoriadis G (Ed.). Informa Healthcare USA Inc., NY, USA, 25-46 (2007).
89. Tardi PG, Gallagher RC, Johnstone S et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim. Biophys. Acta 1768(3), 678-687 (2007).
90. Dicko A, Frazier AA, Liboiron BD et al. Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes. Pharm. Res. 25(7), 1702-1713 (2008).
91. Dicko A, Kwak S, Frazier AA, Mayer LD, Liboiron BD. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int. J. Pharm. 391(1-2), 248-259 (2010).
92. Dicko A, Tardi P, Xie X, Mayer L. Role of copper gluconate/ triethanolamine in irinotecan encapsulation inside the liposomes. Int. J. Pharm. 337(1-2), 219-228 (2007).
93. Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared with analogous normal hematopoietic cells. Exp. Hematol. 39(7), 741-750 (2011).
94. Lim WS, Tardi PG, Dos Santos N et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk. Res. 34(9), 1214-1223 (2010).
95. Ansell SM, Johnstone SA, Tardi PG et al. Development of highly efficacious hydrophobic paclitaxel prodrugs delivered in nanoparticles for fixed-ratio drug combination applications. AACR Meet. Abstr. 5734 (2008).
96. Batist G, Gelmon KA, Chi KN et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 15(2), 692-700 (2009).
97. Cortes JE, Feldman EJ, Goldberg SL et al. CPX-351: a randomized phase iib study of CPX-351 v. intensive salvage therapy in '65 YO first relapse AML patients: initial efficacy and safety report. Blood 118(21), 254 (2011).
98. Lancet JE, Cortes JE, Hogge DE et al. Phase IIB Randomized study of CPX-351 vs. cytarabine (CYT) + daunorubicin (DNR) (7+3 Regimen) in newly diagnosed AML patients aged 60-75. Blood 116(21), 655 (2010).
99. Feldman EJ, Lancet JE, Kolitz JE et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 29(8), 979-985 (2011).
100. Kummar S, Chen HX, Wright J et al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat. Rev. Drug Discov. 9(11), 843-856 (2010).
101. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 5(8), 649-659 (2006).
102. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).